Cediranib maleate (AZD-2171 maleate) is a highly effective, orally administered inhibitor targeting VEGFR with remarkable potency. It demonstrates IC50 values of less than 1 nM for Flt1, below 3 nM for KDR, 5 nM for both Flt4 and PDGFRα, 36 nM for PDGFRβ, and 2 nM for c-Kit, showcasing its broad inhibitory activity across multiple kinase targets.

ADAM17 inhibitor SN-4 is a newly identified, highly specific inhibitor of ADAM17 (A disintegrin and metalloproteinase 17), demonstrating potent activity in blocking TNF-α cleavage in cellular assays with an IC50 value of 3.22 µM. This compound exhibits slightly greater efficacy compared to marimastat, a well-established ADAM17 inhibitor. In vitro studies reveal that SN-4 effectively suppresses ADAM17-mediated cleavage of tumor necrosis factor α (TNF-α) and CD44, while showing no significant impact on ADAM10 activity. Additionally, SN-4 has been shown to inhibit cellular invasion, highlighting its potential as a targeted therapeutic agent for modulating ADAM17-related pathways.

BHC, a small-molecule inhibitor of skeletal muscle myosin, effectively suppresses muscle activity by targeting myosin function without altering membrane currents. This compound emerges from a screening process aimed at identifying molecules capable of modulating muscle movement through myosin inhibition. By specifically inhibiting myosin, BHC provides a unique mechanism for controlling muscle contractions while maintaining the integrity of cellular electrical properties.

Furamidine (DB75) is abisbenzamidine derivative and an antiparasite agent. Furamidine is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine is also a selective and cell-permeable protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 9.4 μM. Furamidine is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC50s of 166 µM, 283 µM, and >400 µM, respectively).

RTI-7470-44 is a highly potent and selective antagonist of the human trace amine-associated receptor 1 (hTAAR1), demonstrating an IC50 of 8.4 nM in an in vitro cAMP functional assay. In radioligand binding studies, it exhibits a Ki value of 0.3 nM, highlighting its strong affinity for hTAAR1. Notably, RTI-7470-44 shows significant species selectivity, with over 90-fold preference for hTAAR1 compared to its rat and mouse counterparts. This compound also possesses favorable pharmacokinetic properties, including good blood-brain barrier penetration, moderate metabolic stability, and a promising off-target safety profile. In electrophysiological studies, RTI-7470-44 enhanced the spontaneous firing rate of dopaminergic neurons in the mouse ventral tegmental area (VTA) and effectively counteracted the effects of the TAAR1 agonist RO5166017.

STM2457 is currently available in stock and ready for immediate shipment. It is a highly effective inhibitor targeting the catalytic activity of METTL3/METTL14, with an IC50 value of 16.9 nM and a Kd value of 1.4 nM. This compound exhibits exceptional specificity for METTL3 and demonstrates notable anti-leukaemic properties.

YB-3−17 is a novel bifunctional molecule, robustly inhibits mTOR (IC50 of 0.22 nM) and selectively degrades GSPT1 (DC50 of 5 nM). YB-3−17 degrades GSPT1 selectively without affecting GSPT2 or SNUPN. YB-3−17 shows significant off-target inhibition of kinases like FGR, CSF1R, LCK, or LYN, unlike MLN0128.

PF-07328948 is a first-in-class branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor with IC50 of 15 nM and shows a high degree selectivity over a number of kinases and other off-targets. PF-07328948 is the first known selective BDK inhibitor candidate to be examined in clinical studies.

PF-07265028 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1) with Ki<0.05 nM and represents >280-fold improvement in biochemical potency while maintaining a comparable lipophilicity.

YK-2168 is a differentiated selective CDK9 inhibitor with IC50 of 5.9 nM, demonstrating 72.5-fold and 45.2-fold selectivity over CDK1 and CDK2, respectively. YK-2168 achieves superior CDK9 selectivity over AZD4573 and comparable selectivity to BAY1251152.

Ferfluor-1 is a novel 1,3,4-thiadiazole-functionalized druglike ferrostatin analogue as a ferroptosis inhibitor and photoluminescent indicator. Ferfluor-1 shows superior anti-ferroptosis potency, favorable BBB permeability and in vivo activity against stroke and Parkinson's disease.

P6CIT is a cationic lipid for targeted mRNA delivery to pancreatic ductal adenocarcinoma (PDAC). Pan-tgt (P6CIT) LNP could specifically deliver mRNA to immune cells in PDAC tissues, including dendritic cells (DCs), macrophages, natural killer (NK) cells, and T cells.

VIP36 is a peripherally restricted cannabinoid receptor type 1 (CB1) agonist with Ki of 22 nM and exerts analgesic efficacy through peripheral CB1 receptors and shows limited analgesic tolerance.

YEATS4 binder 4e stands out as a highly potent and selective small-molecule inhibitor targeting the epigenetic reader YEATS4. It demonstrates a strong binding affinity with a Ki value of 37 nM. Importantly, this compound exhibits remarkable selectivity, showing over 15-fold preference for YEATS4 compared to other members of the YEATS family, including YEATS1, YEATS2, and YEATS3.

Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5).

Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.

Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin.

KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis.

Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke.

Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia.